حجم سوق المثانة غير الفعالة، تقرير البحث والاتجاهات

السوق العالمية للمثانة غير النشطة، حسب النوع (العلاج الدوائي، والطرق الجراحية، وجهاز مساعدة مجرى البول، والعلاجات بالخلايا الجذعية والجينات)، وطريق الإدارة (عن طريق الفم، والحقن، وغيرها)، والمستخدم النهائي (المستشفيات، والعيادات، والمعاهد الأكاديمية والبحثية، وغيرها)، وقناة التوزيع (صيدلية المستشفى، وصيدلية التجزئة، وغيرها) واتجاهات الصناعة والتوقعات حتى عام 2029.

سوق المثانة غير النشطة

تحليل ورؤى حول سوق المثانة غير النشطة

إن سوق المثانة غير النشطة العالمية مدفوع بعوامل مثل ارتفاع حالات الإصابة بعدوى المثانة العصبية ، وزيادة تمويل الأبحاث، وتطوير علاجات جديدة للمثانة غير النشطة (UAB)، ومنتجات خطوط الأنابيب التي تعزز الطلب عليها جنبًا إلى جنب مع زيادة الاستثمار في البحث والتطوير مما يؤدي إلى نمو السوق. حاليًا، زادت نفقات الرعاية الصحية في جميع أنحاء البلدان المتقدمة والناشئة، ومن المتوقع أن يخلق ذلك ميزة تنافسية للشركات المصنعة لتطوير منتجات جديدة ومبتكرة. بالإضافة إلى ذلك، فإن الزيادة في نفقات الرعاية الصحية وزيادة انتشار اضطرابات المثانة تؤثر بشكل إيجابي على السوق.

سوق المثانة غير النشطة

ومع ذلك، فإن التكلفة العالية للعلاج تحد من قدرة المرضى على التكيف مع الحلول عالية الجودة والفعالة. ومن ثم، فإن التكلفة العالية لإجراءات العلاج تؤثر سلبًا على تكلفة العلاج الإجمالي. وعلاوة على ذلك، فإن الأدوية المستخدمة حاليًا لعلاج التهاب الأذن الوسطى الحاد لم يثبت أنها مرضية سريريًا من وجهة نظر الفعالية والسلامة، مما يؤدي إلى الحاجة إلى تطوير عوامل علاجية جديدة.

من المتوقع أن ينمو سوق المثانة غير النشطة العالمي خلال الفترة المتوقعة بسبب زيادة عدد اللاعبين في السوق ووجود أدوية جديدة في خطوط الأنابيب. إلى جانب ذلك، يشارك المصنعون في أنشطة البحث والتطوير لإطلاق منتجات جديدة في السوق.

ومع ذلك، من المتوقع أن تعمل التكلفة العالية المرتبطة بالأبحاث والدراسات على كبح نمو السوق، مما قد يؤثر بشكل أكبر على إطلاق منتجات جديدة في السوق.

إن الزيادة في عدد برامج البحث والتطوير، وارتفاع الشراكات بين القطاعين العام والخاص لتسهيل التطورات الجديدة للعلاج المبتكر والفعال تؤثر بشكل أكبر على السوق.

يقدم تقرير سوق المثانة غير النشطة العالمي تفاصيل عن حصة السوق والتطورات الجديدة وتحليل خط أنابيب المنتجات وتأثير اللاعبين المحليين والمحليين في السوق ويحلل الفرص من حيث جيوب الإيرادات الناشئة والتغييرات في لوائح السوق وموافقات المنتجات والقرارات الاستراتيجية وإطلاق المنتجات والتوسعات الجغرافية والابتكارات التكنولوجية في السوق. لفهم التحليل وسيناريو السوق، اتصل بنا للحصول على موجز محلل، وسيساعدك فريقنا في إنشاء حل لتأثير الإيرادات لتحقيق هدفك المنشود. إن قابلية التوسع وتوسع أعمال وحدات البيع بالتجزئة في البلدان النامية في مختلف المناطق والشراكة مع الموردين للتوزيع الآمن لمنتجات الآلات والأدوية هي المحركات الرئيسية التي دفعت الطلب على السوق في فترة التنبؤ.

إن سوق المثانة غير النشطة العالمية داعمة وتهدف إلى الحد من تطور المرض. تحلل شركة Data Bridge Market Research أن سوق المثانة غير النشطة العالمية ستنمو بمعدل نمو سنوي مركب بنسبة 5.1% خلال الفترة المتوقعة من 2022 إلى 2029.

تقرير القياس	تفاصيل
فترة التنبؤ	2022 إلى 2029
سنة الأساس	2021
سنوات تاريخية	2020
وحدات كمية	الإيرادات بالملايين من الدولارات الأمريكية، التسعير بالدولار الأمريكي
القطاعات المغطاة	حسب النوع (العلاج الدوائي، والطرق الجراحية، وجهاز مساعدة مجرى البول، والعلاجات بالخلايا الجذعية والجينات)، وطريق الإعطاء (عن طريق الفم، والحقن، وغيرها)، والمستخدم النهائي (المستشفيات والعيادات والمعاهد الأكاديمية والبحثية وغيرها)، وقناة التوزيع (صيدليات المستشفيات، وصيدليات التجزئة وغيرها) اتجاهات الصناعة والتوقعات حتى عام 2029
الدول المغطاة	الولايات المتحدة الأمريكية، كندا، المكسيك، ألمانيا، فرنسا، إيطاليا، المملكة المتحدة، إسبانيا، هولندا، روسيا، سويسرا، تركيا، النمسا، النرويج، المجر، ليتوانيا، أيرلندا، بولندا، لوكسمبورج، بقية أوروبا، اليابان، الصين، الهند، كوريا الجنوبية، أستراليا، سنغافورة، ماليزيا، تايلاند، إندونيسيا، الفلبين، فيتنام، بقية دول آسيا والمحيط الهادئ، البرازيل، الأرجنتين، بيرو، بقية دول أمريكا الجنوبية، المملكة العربية السعودية، جنوب أفريقيا، الإمارات العربية المتحدة، إسرائيل، الكويت، مصر، وبقية دول الشرق الأوسط وأفريقيا
الجهات الفاعلة في السوق المشمولة	Astellas Pharma Inc.، وAurobindo Pharma.، وBoehringer Ingelheim International GmbH، وMacleods Pharmaceuticals Ltd.، وOrion Corporation، وONO PHARMACEUTICAL CO., LTD.، وNovartis AG، وPfizer Inc.، وCipla Inc.، وDr. Reddy's Laboratories Ltd.، وTeva Pharmaceutical Industries Ltd.، وSun Pharmaceutical Industries Ltd.، وAlmirall, SA، وGlenwood, Vesiflo, Inc.، وAlkem Labs. من بين شركات أخرى

تعريف السوق

المثانة غير النشطة (UAB) هي حالة سريرية يتطور فيها اضطراب التبول نتيجة لانخفاض انقباض العضلة الدافعة (عضلة المثانة) أثناء التبول. تتميز هذه الحالة بالشعور بالحاجة إلى التبول على الفور، وبالتالي، فإن هذه الحالة تختلف عن المثانة المفرطة النشاط (OAB). يوفر الاختراع الحالي تركيبة صيدلانية مفيدة للوقاية من أو علاج المثانة غير النشطة والتي لها تأثير تحسين معدل تدفق البول، وتأثير تحسين فرط تمدد المثانة (تأثير تقليل سعة المثانة)، وبالتالي، فهي مفيدة للوقاية من أو علاج المثانة غير النشطة.

علاوة على ذلك، فهي حالة مرضية تختلف عن فرط نشاط المثانة الذي يتميز بالحاجة الملحة للتبول والتي جذبت الانتباه في السنوات الأخيرة. تشمل أسباب فرط نشاط المثانة الاعتلال العصبي اللاإرادي مثل مرض السكري وإدمان الكحول، وجراحة الحوض مثل استئصال الرحم الجذري وسرطان المستقيم الجذري، وأمراض الحبل الشوكي مثل السنسنة المشقوقة، كما يُعرف أيضًا انفتاق القرص. يحتاج المرضى الذين يعانون من مشاكل شديدة وخفيفة مرتبطة باضطراب المثانة إلى العلاج الدوائي الذي غالبًا ما يكون متناوبًا مع علاجات متعددة وبدون راحة كافية مع تلقي العلاجات المستمرة، مما يخلق أيضًا تأثيرًا على نفقات الرعاية الصحية.

ديناميكيات سوق المثانة غير النشطة العالمية

يتناول هذا القسم فهم محركات السوق والفرص والقيود والتحديات. وسيتم مناقشة كل ذلك بالتفصيل أدناه:

السائقين

تزايد انتشار الاضطرابات العصبية

إن فرط التبول اللاإرادي هو حالة عصبية شائعة لا تعمل فيها الأعصاب والعضلات معًا بشكل جيد مما يؤدي إلى إطالة وقت التبول مع أو بدون الشعور بعدم إفراغ المثانة بالكامل. في هذه الحالة، لا تؤدي عضلات المثانة إلى نشاطها الانقباضي الذي يتميز بتدفق البول البطيء والتردد والإجهاد لإفراغ المثانة، مع أو بدون الشعور بعدم إفراغ المثانة بالكامل، وأحيانًا مع أعراض التخزين. وبالتالي، فإن المثانة إما لا تفرغ أو تفرغ جزئيًا فقط وهو ما يرجع إلى عدم قدرة عضلات المثانة على إخراج البول بشكل صحيح.

نتيجة لذلك، قد يعاني مرضى فرط نشاط المثانة من أعراض مختلفة للتبول وقد يصاحبهم كمية كبيرة من البول المتبقي. غالبًا ما تُرى مضاعفات احتباس البول بسبب التفاقم والتهابات المسالك البولية (UTIs) بسبب البول المتبقي المزمن وأصبحت مشكلة. علاوة على ذلك، فهي حالة مرضية تختلف عن فرط نشاط المثانة التي تتميز بالإلحاح البولي والتي كانت تجذب الانتباه في السنوات الأخيرة. وبالتالي، من المتوقع أن يؤدي الانتشار المتزايد لاضطرابات المثانة العصبية إلى دفع نمو السوق. سيؤدي هذا إلى زيادة الطلب على العلاج الذي يمكنه اكتشاف المرضى أيضًا، ونتيجة لذلك من المتوقع أن يكون هناك نمو مربح في السوق.

ارتفاع الإنفاق على الرعاية الصحية

إن الأدوات والقوى العاملة والإدارة الطبية في حالة حدوث أي ضرر للباحثين والتأمين والنقل ورسوم لجنة الأخلاقيات ومعالجة البيانات والمواد الاستهلاكية الأخرى تؤدي إلى تكاليف كبيرة للاعبين في السوق. يشمل الإنفاق على الرعاية الصحية جميع خدمات الرعاية الصحية وأجهزة الاختبار وأنشطة تنظيم الأسرة والمساعدات الطارئة المخصصة للصحة. توفر الحسابات الصحية الوطنية العديد من المؤشرات بناءً على الإنفاق الذي تم جمعه في إطار معترف به دوليًا. العوامل التي تحدد الإنفاق على الرعاية الصحية في أي بلد هي الدخل (الناتج المحلي الإجمالي للفرد) والتقدم التكنولوجي والاختلاف في الممارسة الطبية وخصائص أنظمة الصحة.

يساعد ارتفاع الإنفاق على الرعاية الصحية في نفس الوقت منظمات الرعاية الصحية والهيئات الحكومية على زيادة أنشطة البحث في أدوية انقطاع الطمث، والتجارب السريرية القادمة، وأنشطة البحث والتطوير. كما تتطلب التكلفة المترتبة على إنتاج وتصنيع المنتجات الجديدة، واللاعبين في السوق تخصيصًا كافيًا للأموال والموارد، وبالتالي، تعمل الحكومة كيد مساعدة في هذا السيناريو. كما أن زيادة الإنفاق على الرعاية الصحية مفيدة أيضًا لمزيد من التنمية الاقتصادية ونمو قطاع الرعاية الصحية. بالإضافة إلى ذلك، فإن الزيادة في الدخل المتاح للسكان هي عامل إيجابي. وبالتالي، من المتوقع أن يؤدي ارتفاع الإنفاق على الرعاية الصحية إلى دفع نمو السوق في المستقبل.

سوق المثانة غير النشطة

فرصة

ارتفاع المضاعفات البولية لمرض السكري

تشمل الأسباب المعروفة لمرض UAB الاعتلال العصبي اللاإرادي مثل مرض السكري. علاوة على ذلك، يرتبط مرض السكري بظهور مبكر وزيادة شدة أمراض المسالك البولية التي تؤدي إلى مضاعفات مسالك بولية مكلفة ومنهكة. هذه المضاعفات المسالك البولية، بما في ذلك خلل المثانة والتهابات المسالك البولية وغيرها، لها تأثير عميق على نوعية حياة كل من الرجال والنساء المصابين بمرض السكري. مرض السكري وأمراض المسالك البولية هي مشاكل صحية شائعة جدًا تزداد انتشارها ووقوعها بشكل ملحوظ مع تقدم العمر. المضاعفات البولية لمرض السكري هي تأثير فوري. مرض السكري هو الاضطراب الأكثر شهرة وله انتشار مرتفع على مستوى العالم.

يمكن أن تنجم مضاعفات المثانة المرتبطة بمرض السكري عن تناوب في عضلات المثانة الملساء، وخلل في الخلايا العصبية، وخلل في الخلايا البولية. واعتمادًا على الأعصاب المعنية، يمكن أن تتراوح تأثيرات الاعتلال العصبي السكري من عدم الراحة والخدر في الساقين إلى مضاعفات في الجهاز الهضمي، والمسالك البولية، والأوعية الدموية، والجذع. ستؤدي البيانات المتزايدة حول مرض السكري إلى زيادة كبيرة في خطر حدوث مضاعفات المسالك البولية لمرض السكري في جميع أنحاء العالم. وبالتالي، من المطلوب التوصية بالاتجاهات المستقبلية للبحث والرعاية السريرية للعلاج المناسب لمضاعفات المسالك البولية لمرض السكري. كما ستكون هناك حاجة إلى الدعم من المنظمات الأخرى للوصول إلى المناطق غير المتقدمة لمعالجة المضاعفات المهملة. لذلك، فإن هذا يعني أن ارتفاع المضاعفات البولية لمرض السكري من المتوقع أن يعمل كفرصة لنمو السوق.

ضبط النفس/التحدي

ارتفاع تكلفة البحث والتطوير

إن البحث والتطوير شرط أساسي لتعديل الإجراء المخصص لعلاج أنواع مختلفة من المرضى. وتتطلب التكلفة الأعلى للبحث والتطوير للمنتجات الجديدة إجراء أبحاث عميقة ودراسات سريرية. وتتطلب المراحل السريرية المختلفة في البحث والتطوير استثمارات ضخمة يمكن أن تؤثر على نمو السوق. وتتطلب تكلفة البحث المشاركة في التخطيط للدراسات وتنفيذها، كما يتطلب البحث تخصيصًا كافيًا للأموال والموارد، مما قد يؤثر على التطورات الجديدة في السوق. تلعب تكلفة المنتج عاملاً رئيسيًا في السوق. تتوفر العديد من خيارات التشخيص في السوق، ولكن نظرًا لتكلفتها المرتفعة، يميل معظم الناس إلى تجنب إجراء التشخيص. وقد جاءت الأساليب التشخيصية بحساسية وخصوصية أكبر، كما زادت تكلفة الاختبار.

إن التكلفة العالية لهذا الإجراء ترجع إلى نقاط التفتيش المختلفة للعلاجات إلى جانب استخدام الوسائل التكنولوجية العالية لإجراء مثل هذه الإجراءات. ونظرًا لأن تكلفة البحث والتطوير للعلاجات مرتفعة للغاية، فإنها تحد من استيعاب الحلول عالية الجودة والفعالة. ومن ثم، فإن التكلفة المرتفعة تؤثر سلبًا على تكلفة العلاج بشكل عام. وبالتالي، فإنها ستحد من الطلب المستقبلي على العلاج في البلدان المنخفضة والمتوسطة الدخل. وهذا يشير إلى أن التكلفة المرتفعة المرتبطة بالبحث والدراسات من المتوقع أن تحد من نمو السوق مما قد يؤثر بشكل أكبر على إطلاق منتجات جديدة في السوق.

تأثير ما بعد كوفيد-19 على سوق المثانة غير النشطة العالمية

لقد أثر فيروس كورونا المستجد بشكل إيجابي على نمو السوق حيث ارتفع الطلب على المنتجات على نطاق واسع في المنطقة. أصبح الناس أكثر وعياً بالصحة حيث يوجد انتشار متزايد لأمراض المثانة المختلفة في المنطقة. غالبًا ما تُرى مضاعفات احتباس البول بسبب التفاقم والتهابات المسالك البولية بسبب البول المتبقي المزمن وأصبحت مشكلة. وبالتالي، كان لفيروس كورونا المستجد تأثير إيجابي على هذا السوق.

التطورات الأخيرة

في يونيو 2020، أعلنت شركة Vesiflo, Inc. عن تغطية التأمين الصحي لدعامة البول الداخلية، وهي جهاز صمام داخل مجرى البول معتمد من إدارة الغذاء والدواء الأمريكية ومقترن مغناطيسيًا ويمكن استخدامه لمدة 29 يومًا من قبل النساء البالغات كبديل للقسطرة المتقطعة. ويؤدي هذا إلى المساهمة في توسيع نطاق أعمال المنتج بسرعة مع تسويقه في السوق.
في أبريل 2020، أكملت شركة Astellas Pharma Europe Ltd. تجربة سريرية أجريت على مرضى لعلاج قلة نشاط المثانة. حاليًا، يخضع ASP8302 للتجربة السريرية للمرحلة الثانية للتحقيق في سلامة الدواء وتحمله لدى المرضى الذين يعانون من قلة نشاط المثانة.

نطاق سوق المثانة غير النشطة العالمية

يتم تصنيف سوق المثانة غير النشطة العالمية إلى أربعة قطاعات بارزة بناءً على النوع وطريقة الإدارة والمستخدم النهائي وقناة التوزيع. يساعدك النمو بين القطاعات على تحليل جيوب النمو والاستراتيجيات المتخصصة للتعامل مع السوق وتحديد مجالات التطبيق الأساسية والاختلاف في الأسواق المستهدفة.

يكتب

العلاج الدوائي
الأساليب الجراحية
جهاز مساعدة مجرى البول
العلاج بالخلايا الجذعية والجينات

بناءً على العلاج، يتم تقسيم السوق إلى العلاج الدوائي، والطرق الجراحية، وجهاز مساعدة مجرى البول، والعلاجات بالخلايا الجذعية والجينات.

طريق الإدارة

شفوي
الحقن الوريدي
آحرون

بناءً على طريق الإدارة، يتم تقسيم السوق إلى فموي، وحقني، وغيرها.

المستخدم النهائي

المستشفيات
العيادات
المؤسسات الأكاديمية والبحثية
آحرون

بناءً على المستخدم النهائي، يتم تقسيم السوق إلى المستشفيات والعيادات والمعاهد الأكاديمية والبحثية وغيرها.

قناة التوزيع

صيدلية المستشفى
صيدلية التجزئة
آحرون

سوق المثانة غير النشطة

بناءً على قناة التوزيع، يتم تقسيم السوق إلى صيدلية المستشفيات، وصيدلية التجزئة، وغيرها.

تحليل إقليمي/رؤى حول سوق المثانة غير النشطة العالمية

يتم تحليل سوق المثانة غير النشطة العالمية وتوفير رؤى حجم السوق والاتجاهات حسب النوع وطريقة الإدارة والمستخدم النهائي وقناة التوزيع كما هو مذكور أعلاه.

الدول التي يغطيها تقرير سوق المثانة غير النشطة العالمي هي الولايات المتحدة وكندا والمكسيك وألمانيا وفرنسا وإيطاليا والمملكة المتحدة وإسبانيا وهولندا وروسيا وسويسرا وتركيا والنمسا والنرويج والمجر وليتوانيا وأيرلندا وبولندا ولوكسمبورج وبقية أوروبا واليابان والصين والهند وكوريا الجنوبية وأستراليا وسنغافورة وماليزيا وتايلاند وإندونيسيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ والبرازيل والأرجنتين وبيرو وبقية دول أمريكا الجنوبية والمملكة العربية السعودية وجنوب إفريقيا والإمارات العربية المتحدة وإسرائيل والكويت ومصر وبقية دول الشرق الأوسط وأفريقيا.

من المتوقع أن تهيمن أمريكا الشمالية على السوق في عام 2022 بسبب الانتشار المتزايد لاضطرابات المثانة والتواجد المتزايد للاعبين في السوق في المنطقة.

ومن المتوقع أن تهيمن الولايات المتحدة على منطقة أمريكا الشمالية بسبب وجود لاعبين رئيسيين في البلاد وارتفاع عدد مرافق التصنيع. ومن المتوقع أن تهيمن ألمانيا على منطقة أوروبا بسبب وجود لاعبين كبار في السوق ونظام رعاية صحية راسخ لعلاج اضطرابات المثانة. ومن المتوقع أن تهيمن الصين على منطقة آسيا والمحيط الهادئ بسبب وجود لاعبين كبار في السوق ونظام رعاية صحية راسخ لعلاج اضطرابات المثانة.

سوق المثانة غير النشطة

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغيرات في تنظيم السوق التي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل تحليل سلسلة القيمة في المصب والمصب، والاتجاهات الفنية، وتحليل قوى بورتر الخمس، ودراسات الحالة بعض المؤشرات المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية العالمية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية، وتأثير التعريفات الجمركية المحلية وطرق التجارة أثناء تقديم تحليل توقعات لبيانات الدولة.

تحليل المشهد التنافسي وحصة سوق المثانة غير النشطة العالمية

يقدم المشهد التنافسي العالمي لسوق المثانة غير النشطة تفاصيل عن المنافسين. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات على سوق المثانة غير النشطة العالمية.

بعض اللاعبين الرئيسيين العاملين في السوق هم

شركة استيلاس فارما
أوروبيندو فارما
شركة بوهرينغر إنجلهايم الدولية المحدودة
شركة ماكلويدز للأدوية المحدودة
شركة اوريون
شركة أونو للأدوية المحدودة
شركة نوفارتيس ايه جي
شركة فايزر
شركة سيبلا
مختبرات الدكتور ريدي المحدودة
شركة تيفا للصناعات الدوائية المحدودة
شركة صن للصناعات الدوائية المحدودة
ألميرال، جنوب أستراليا
جلينوود
شركة فيسيفلو
مختبرات ألكيم

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. بالإضافة إلى ذلك، يعد تحليل حصة السوق وتحليل الاتجاهات الرئيسية من عوامل النجاح الرئيسية في تقرير السوق. منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي مثلث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأساسي (خبير الصناعة). وبصرف النظر عن هذا، تتضمن نماذج البيانات شبكة وضع البائعين وتحليل الخط الزمني للسوق ونظرة عامة على السوق والدليل وشبكة وضع الشركة وتحليل حصة الشركة في السوق ومعايير القياس والتحليل العالمي مقابل الإقليمي وتحليل حصة البائعين. يرجى طلب مكالمة محلل في حالة وجود استفسار آخر.

SKU-59873

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

انقر على الصورة للتكبير

لوحة معلومات تحليل البيانات التفاعلية
لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
تحليل المنافسين باستخدام لوحة معلومات تفاعلية
آخر الأخبار والتحديثات وتحليل الاتجاهات
استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل

طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL UNDERACTIVE BLADDER MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 EPIDEMIOLOGY

4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-

4.4.1 DOXAZOSIN

4.4.2 BETHANECHOL CHLORIDE

4.4.3 TAMSULOSIN HYDROCHLORIDE

4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER

4.5.1 EU CLINICAL TRIALS REGISTER-

4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY

4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:

4.8 CROSS-BORDER DEALS:

4.9 OUTLOOK FOR 2022:

4.1 PATIENT ENROLMENT STRATEGIES

4.11 FACTORS AFFECTING PATIENT RECRUITMENT:

4.12 CHALLENGES:

4.13 PATIENT FUNNEL ANALYSIS:

4.14 RECOMMENDATIONS

4.14.1 USE OF TECHNOLOGY:

4.14.2 PARTICIPANT CHARACTERISTICS:

4.14.3 RECRUITER CHARACTERISTICS:

4.14.4 SYSTEMS & PROCEDURES:

4.14.5 LOCATION:

4.14.6 NATURE OF RESEARCH:

4.15 CONCLUSION:

4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM

4.17 WHAT CAUSES UNDERACTIVE BLADDER?

4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE

4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER

4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-

5 GLOBAL UNDERACTIVE BLADDER MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER

6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT

6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO

6.1.4 RISING HEALTHCARE EXPENDITURE

6.2 RESTRAINTS

6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT

6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL

6.3 OPPORTUNITIES

6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES

6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS

6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM

6.4 CHALLENGES

6.4.1 LACK OF PROPER TREATMENT

6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER

7 GLOBAL UNDERACTIVE BLADDER MARKET, BY TYPE

7.1 OVERVIEW

7.2 PHARMACOTHERAPY

7.2.1 ALPHA-BLOCKERS

7.2.2 MUSCARINIC AGONISTS

7.2.3 CHOLINESTERASE INHIBITOR

7.2.3.1 BY DRUGS

7.2.3.1.1 TAMSULOSIN

7.2.3.1.2 DOXAZOSIN

7.2.3.1.3 DISTIGMINE

7.2.3.1.4 BETHANECHOL

7.2.3.1.5 OTHERS

7.2.4 BY PRODUCT TYPES

7.2.4.1 GENERICS

7.2.4.2 BRANDED

7.2.4.2.1 FLOMAX

7.2.4.2.2 ALFADIL

7.2.4.2.3 GRAVITOR

7.2.4.2.4 URIVOID

7.2.4.2.5 OTHERS

7.3 SURGICAL METHODS

7.3.1 SURGICAL NERVE STIMULATION

7.3.2 REDUCTION CYSTOPLASTY

7.3.3 SURGERIES FOR BLADDER OBSTRUCTION

7.3.4 INJECTION INTO EXTERNAL SPHINCTER

7.3.5 OTHERS

7.4 URETHRAL ASSIS DEVICE

7.4.1 INFLOW INTRAURETHRAL VALVE PUMP

7.5 STEM CELL AND GENE THERAPIES

7.5.1 NERVE GROWTH FACTOR

7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL

7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS

8 GLOBAL UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 PARENTERAL

8.3 ORAL

8.4 OTHERS

9 GLOBAL UNDERACTIVE BLADDER MARKET , BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 CLINICS

9.4 ACADEMIC AND RESEARCH

9.5 OTHERS

10 GLOBAL UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACY

10.3 RETAIL PHARMACY

10.4 OTHERS

11 GLOBAL UNDERACTIVE BLADDER MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S.

11.2.2 CANADA

11.2.3 MEXICO

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 U.K.

11.3.4 ITALY

11.3.5 RUSSIA

11.3.6 SPAIN

11.3.7 TURKEY

11.3.8 NETHERLANDS

11.3.9 SWITZERLAND

11.3.10 POLAND

11.3.11 AUSTRIA

11.3.12 HUNGARY

11.3.13 NORWAY

11.3.14 IRELAND

11.3.15 LITHUANIA

11.3.16 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 SOUTH KOREA

11.4.5 AUSTRALIA

11.4.6 SINGAPORE

11.4.7 THAILAND

11.4.8 INDONESIA

11.4.9 PHILIPPINES

11.4.10 MALAYSIA

11.4.11 VIETNAM

11.4.12 REST OF ASIA-PACIFIC

11.5 SOUTH AMERICA

11.5.1 BRAZIL

11.5.2 ARGENTINA

11.5.3 PERU

11.5.4 REST OF SOUTH AMERICA

11.6 MIDDLE EAST AND AFRICA

11.6.1 SOUTH AFRICA

11.6.2 SAUDI ARABIA

11.6.3 U.A.E

11.6.4 ISRAEL

11.6.5 EGYPT

11.6.6 KUWAIT

11.6.7 REST OF MIDDLE EAST AND AFRICA

12 GLOBAL UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILES

14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.1.1 COMPANY SNAPSHOT

14.1.2 COMPANY SHARE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENT

14.2 PFIZER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 NOVARTIS AG

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 DR. REDDY’S LABORATORIES LTD.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 ASTELLAS PHARMA INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 ORION CORPORATION.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENT

14.9 ALKEM LABS.

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.9.4 RECENT DEVELOPMENT

14.1 ALMIRALL, S.A

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.11 AUROBINDO PHARMA.

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 CIPLA INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENT

14.13 GLENWOOD

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MACLEODS PHARMACEUTICALS LTD.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

14.15 ONO PHARMACEUTICAL CO., LTD.

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENT

14.16 VESIFLO, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET

TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET

TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY

TABLE 4 TOTAL 58 DRUGS DISCONTINUED

TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY

TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-

TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-

TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:

TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 10 GLOBAL UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)

TABLE 28 GLOBAL HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 GLOBAL CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 GLOBAL ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 GLOBAL OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 GLOBAL UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 33 GLOBAL HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 GLOBAL RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 GLOBAL OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 GLOBAL UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 40 NORTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 41 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 42 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 43 NORTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 44 NORTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 45 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 46 NORTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 47 NORTH AMERICA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 48 NORTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 49 NORTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 50 NORTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 51 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 52 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 53 NORTH AMERICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 54 U.S. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 56 U.S. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 57 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 58 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 59 U.S. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 60 U.S. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 61 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 62 U.S. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 63 U.S. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 64 U.S. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 65 U.S. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 66 U.S. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 67 U.S. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 68 U.S. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 69 U.S. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 70 CANADA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 72 CANADA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 73 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 74 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 75 CANADA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 76 CANADA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 77 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 78 CANADA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 79 CANADA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 80 CANADA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 81 CANADA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 82 CANADA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 83 CANADA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 84 CANADA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 85 CANADA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 86 MEXICO UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 88 MEXICO PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 89 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 90 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 91 MEXICO BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 92 MEXICO BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 93 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 94 MEXICO BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 95 MEXICO BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 96 MEXICO SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 97 MEXICO URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 98 MEXICO STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 99 MEXICO UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 100 MEXICO UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 101 MEXICO UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 102 EUROPE UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 103 EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 105 EUROPE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 106 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 107 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 108 EUROPE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 109 EUROPE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 110 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 111 EUROPE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 112 EUROPE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 113 EUROPE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 114 EUROPE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 115 EUROPE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 116 EUROPE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 117 EUROPE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 118 EUROPE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 119 GERMANY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 121 GERMANY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 122 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 123 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 124 GERMANY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 125 GERMANY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 126 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 127 GERMANY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 128 GERMANY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 129 GERMANY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 130 GERMANY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 131 GERMANY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 132 GERMANY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 133 GERMANY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 134 GERMANY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 135 FRANCE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 137 FRANCE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 138 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 139 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 140 FRANCE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 141 FRANCE BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 142 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 143 FRANCE BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 144 FRANCE BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 145 FRANCE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 146 FRANCE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 147 FRANCE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 148 FRANCE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 149 FRANCE UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 150 FRANCE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 151 U.K. UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 153 U.K. PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 154 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 155 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 156 U.K. BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 157 U.K. BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 158 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 159 U.K. BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 160 U.K. BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 161 U.K. SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 162 U.K. URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 163 U.K. STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 164 U.K. UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 165 U.K. UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 166 U.K. UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 167 ITALY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 168 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 169 ITALY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 170 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 171 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 172 ITALY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 173 ITALY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 174 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 175 ITALY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 176 ITALY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 177 ITALY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 178 ITALY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 179 ITALY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 180 ITALY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 181 ITALY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 182 ITALY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 183 RUSSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 184 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 185 RUSSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 186 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 187 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 188 RUSSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 189 RUSSIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 190 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 191 RUSSIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 192 RUSSIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 193 RUSSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 194 RUSSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 195 RUSSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 196 RUSSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 197 RUSSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 198 RUSSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 199 SPAIN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 201 SPAIN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 202 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 203 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 204 SPAIN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 205 SPAIN BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 206 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 207 SPAIN BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 208 SPAIN BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 209 SPAIN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 210 SPAIN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 211 SPAIN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 212 SPAIN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 213 SPAIN UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 214 SPAIN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 215 TURKEY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 216 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 217 TURKEY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 218 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 219 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 220 TURKEY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 221 TURKEY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 222 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 223 TURKEY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 224 TURKEY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 225 TURKEY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 226 TURKEY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 227 TURKEY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 228 TURKEY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 229 TURKEY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 230 TURKEY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 231 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 232 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 233 NETHERLANDS PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 234 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 235 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 236 NETHERLANDS BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 237 NETHERLANDS BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 238 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 239 NETHERLANDS BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 240 NETHERLANDS BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 241 NETHERLANDS SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 242 NETHERLANDS URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 243 NETHERLANDS STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 244 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 245 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 246 NETHERLANDS UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 247 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 248 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 249 SWITZERLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 250 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 251 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 252 SWITZERLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 253 SWITZERLAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 254 SWITZERLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 255 SWITZERLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 256 SWITZERLAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 257 SWITZERLAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 258 SWITZERLAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 259 SWITZERLAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 260 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 261 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 262 SWITZERLAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 263 POLAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 264 POLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 265 POLAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 266 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 267 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 268 POLAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 269 POLAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 270 POLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 271 POLAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 272 POLAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 273 POLAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 274 POLAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 275 POLAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 276 POLAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 277 POLAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 278 POLAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 279 AUSTRIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 280 AUSTRIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 281 AUSTRIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 282 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 283 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 284 AUSTRIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 285 AUSTRIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 286 AUSTRIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 287 AUSTRIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 288 AUSTRIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 289 AUSTRIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 290 AUSTRIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 291 AUSTRIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 292 AUSTRIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 293 AUSTRIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 294 AUSTRIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 295 HUNGARY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 296 HUNGARY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 297 HUNGARY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 298 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 299 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 300 HUNGARY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 301 HUNGARY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 302 HUNGARY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 303 HUNGARY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 304 HUNGARY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 305 HUNGARY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 306 HUNGARY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 307 HUNGARY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 308 HUNGARY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 309 HUNGARY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 310 HUNGARY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 311 NORWAY UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 312 NORWAY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 313 NORWAY PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 314 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 315 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 316 NORWAY BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 317 NORWAY BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 318 NORWAY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 319 NORWAY BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 320 NORWAY BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 321 NORWAY SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 322 NORWAY URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 323 NORWAY STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 324 NORWAY UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 325 NORWAY UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 326 NORWAY UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 327 IRELAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 328 IRELAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 329 IRELAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 330 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 331 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 332 IRELAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 333 IRELAND BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 334 IRELAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 335 IRELAND BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 336 IRELAND BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 337 IRELAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 338 IRELAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 339 IRELAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 340 IRELAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 341 IRELAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 342 IRELAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 343 LITHUANIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 344 LITHUANIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 345 LITHUANIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 346 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 347 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 348 LITHUANIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 349 LITHUANIA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 350 LITHUANIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 351 LITHUANIA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 352 LITHUANIA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 353 LITHUANIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 354 LITHUANIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 355 LITHUANIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 356 LITHUANIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 357 LITHUANIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 358 LITHUANIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 359 REST OF EUROPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 360 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 361 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 362 ASIA-PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 363 ASIA-PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 364 ASIA-PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 365 ASIA-PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 366 ASIA-PACIFIC BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 367 ASIA-PACIFIC BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 368 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 369 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 370 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 371 ASIA-PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 372 ASIA-PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 373 ASIA-PACIFIC STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 374 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 375 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 376 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 377 CHINA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 378 CHINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 379 CHINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 380 CHINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 381 CHINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 382 CHINA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 383 CHINA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 384 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 385 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 386 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 387 CHINA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 388 CHINA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 389 CHINA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 390 CHINA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 391 CHINA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 392 CHINA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 393 JAPAN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 394 JAPAN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 395 JAPAN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 396 JAPAN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 397 JAPAN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 398 JAPAN BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 399 JAPAN BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 400 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 401 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 402 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 403 JAPAN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 404 JAPAN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 405 JAPAN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 406 JAPAN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 407 JAPAN UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 408 JAPAN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 409 INDIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 410 INDIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 411 INDIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 412 INDIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 413 INDIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 414 INDIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 415 INDIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 416 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 417 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 418 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 419 INDIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 420 INDIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 421 INDIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 422 INDIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 423 INDIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 424 INDIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 425 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 426 SOUTH KOREA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 427 SOUTH KOREA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 428 SOUTH KOREA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 429 SOUTH KOREA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 430 SOUTH KOREA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 431 SOUTH KOREA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 432 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 433 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 434 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 435 SOUTH KOREA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 436 SOUTH KOREA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 437 SOUTH KOREA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 438 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 439 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 440 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 441 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 442 AUSTRALIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 443 AUSTRALIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 444 AUSTRALIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 445 AUSTRALIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 446 AUSTRALIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 447 AUSTRALIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 448 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 449 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 450 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 451 AUSTRALIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 452 AUSTRALIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 453 AUSTRALIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 454 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 455 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 456 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 457 SINGAPORE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 458 SINGAPORE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 459 SINGAPORE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 460 SINGAPORE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 461 SINGAPORE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 462 SINGAPORE BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 463 SINGAPORE BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 464 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 465 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 466 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 467 SINGAPORE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 468 SINGAPORE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 469 SINGAPORE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 470 SINGAPORE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 471 SINGAPORE UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 472 SINGAPORE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 473 THAILAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 474 THAILAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 475 THAILAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 476 THAILAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 477 THAILAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 478 THAILAND BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 479 THAILAND BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 480 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 481 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 482 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 483 THAILAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 484 THAILAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 485 THAILAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 486 THAILAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 487 THAILAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 488 THAILAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 489 INDONESIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 490 INDONESIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 491 INDONESIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 492 INDONESIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 493 INDONESIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 494 INDONESIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 495 INDONESIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 496 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 497 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 498 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 499 INDONESIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 500 INDONESIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 501 INDONESIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 502 INDONESIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 503 INDONESIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 504 INDONESIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 505 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 506 PHILIPPINES PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 507 PHILIPPINES PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 508 PHILIPPINES BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 509 PHILIPPINES BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 510 PHILIPPINES BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 511 PHILIPPINES BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 512 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 513 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 514 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 515 PHILIPPINES SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 516 PHILIPPINES URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 517 PHILIPPINES STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 518 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 519 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 520 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 521 MALAYSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 522 MALAYSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 523 MALAYSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 524 MALAYSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 525 MALAYSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 526 MALAYSIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 527 MALAYSIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 528 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 529 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 530 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 531 MALAYSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 532 MALAYSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 533 MALAYSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 534 MALAYSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 535 MALAYSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 536 MALAYSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 537 VIETNAM UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 538 VIETNAM PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 539 VIETNAM PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 540 VIETNAM BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 541 VIETNAM BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 542 VIETNAM BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 543 VIETNAM BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 544 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 545 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 546 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 547 VIETNAM SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 548 VIETNAM URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 549 VIETNAM STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 550 VIETNAM UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 551 VIETNAM UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 552 VIETNAM UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 553 REST OF ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 554 SOUTH AMERICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 555 SOUTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 556 SOUTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 557 SOUTH AMERICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 558 SOUTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 559 SOUTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 560 SOUTH AMERICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 561 SOUTH AMERICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 562 SOUTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 563 SOUTH AMERICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 564 SOUTH AMERICA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 565 SOUTH AMERICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 566 SOUTH AMERICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 567 SOUTH AMERICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 568 SOUTH AMERICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 569 SOUTH AMERICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 570 SOUTH AMERICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 571 BRAZIL UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 572 BRAZIL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 573 BRAZIL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 574 BRAZIL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 575 BRAZIL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 576 BRAZIL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 577 BRAZIL BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 578 BRAZIL BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 579 BRAZIL BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 580 BRAZIL BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 581 BRAZIL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 582 BRAZIL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 583 BRAZIL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 584 BRAZIL UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 585 BRAZIL UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 586 BRAZIL UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 587 ARGENTINA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 588 ARGENTINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 589 ARGENTINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 590 ARGENTINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 591 ARGENTINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 592 ARGENTINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 593 ARGENTINA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 594 ARGENTINA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 595 ARGENTINA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 596 ARGENTINA BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 597 ARGENTINA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 598 ARGENTINA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 599 ARGENTINA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 600 ARGENTINA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 601 ARGENTINA UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 602 ARGENTINA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 603 PERU UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 604 PERU PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 605 PERU PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 606 PERU BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 607 PERU BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 608 PERU BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (ASP)

TABLE 609 PERU BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 610 PERU BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 611 PERU BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (UNITS)

TABLE 612 PERU BRANDED TYPES IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 613 PERU SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 614 PERU URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 615 PERU STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 616 PERU UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020- 2029 (USD MILLION)

TABLE 617 PERU UNDERACTIVE BLADDER MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 618 PERU UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 619 REST OF SOUTH AMERICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 620 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 621 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 622 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 623 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 624 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 625 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 626 MIDDLE EAST AND AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 627 MIDDLE EAST AND AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 628 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 629 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 630 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 631 MIDDLE EAST AND AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 632 MIDDLE EAST AND AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 633 MIDDLE EAST AND AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 634 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 635 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 636 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 637 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 638 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 639 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 640 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 641 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 642 SOUTH AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 643 SOUTH AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 644 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 645 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 646 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 647 SOUTH AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 648 SOUTH AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 649 SOUTH AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 650 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 651 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 652 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 653 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 654 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 655 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 656 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 657 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 658 SAUDI ARABIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 659 SAUDI ARABIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 660 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 661 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 662 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 663 SAUDI ARABIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 664 SAUDI ARABIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 665 SAUDI ARABIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 666 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 667 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 668 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 669 U.A.E UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 670 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 671 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 672 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 673 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 674 U.A.E BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 675 U.A.E BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 676 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 677 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 678 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 679 U.A.E SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 680 U.A.E URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 681 U.A.E STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 682 U.A.E UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 683 U.A.E UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 684 U.A.E UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 685 ISRAEL UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 686 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 687 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 688 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 689 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 690 ISRAEL BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 691 ISRAEL BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 692 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 693 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 694 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 695 ISRAEL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 696 ISRAEL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 697 ISRAEL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 698 ISRAEL UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 699 ISRAEL UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 700 ISRAEL UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 701 EGYPT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 702 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 703 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 704 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 705 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 706 EGYPT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 707 EGYPT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 708 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 709 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 710 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 711 EGYPT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 712 EGYPT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 713 EGYPT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 714 EGYPT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 715 EGYPT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 716 EGYPT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 717 KUWAIT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 718 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 719 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 720 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 721 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 722 KUWAIT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 723 KUWAIT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 724 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 725 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 726 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 727 KUWAIT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 728 KUWAIT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 729 KUWAIT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 730 KUWAIT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 731 KUWAIT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 732 KUWAIT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 733 REST OF MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 GLOBAL UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 2 GLOBAL UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL UNDERACTIVE BLADDER MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL UNDERACTIVE BLADDER MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 GLOBAL UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL UNDERACTIVE BLADDER MARKET AND GROW WITH HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE GLOBAL UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD

FIGURE 13 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UNDERACTIVE BLADDER MARKET IN 2022 & 2029

FIGURE 14 NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR FOR THE GLOBAL UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL UNDERACTIVE BLADDER MARKET

FIGURE 16 GLOBAL UNDERACTIVE BLADDER MARKET : TYPE, 2021

FIGURE 17 GLOBAL UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)

FIGURE 18 GLOBAL UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)

FIGURE 19 GLOBAL UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021

FIGURE 21 GLOBAL UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 22 GLOBAL UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 23 GLOBAL UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 24 GLOBAL UNDERACTIVE BLADDER MARKET : BY END USER, 2021

FIGURE 25 GLOBAL UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 26 GLOBAL UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)

FIGURE 27 GLOBAL UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE

FIGURE 28 GLOBAL UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021

FIGURE 29 GLOBAL UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 30 GLOBAL UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 31 GLOBAL UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 32 GLOBAL UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 33 GLOBAL UNDERACTIVE BLADDER MARKET: BY REGION (2021)

FIGURE 34 GLOBAL UNDERACTIVE BLADDER MARKET: BY REGION (2022 & 2029)

FIGURE 35 GLOBAL UNDERACTIVE BLADDER MARKET: BY REGION (2021 & 2029)

FIGURE 36 GLOBAL UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 37 NORTH AMERICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 38 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 39 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 40 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 41 NORTH AMERICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 42 EUROPE UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 43 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 44 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 EUROPE UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 EUROPE UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 47 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 48 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 49 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 50 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 51 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 52 SOUTH AMERICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 53 SOUTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 54 SOUTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 55 SOUTH AMERICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 56 SOUTH AMERICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 57 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 58 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 59 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 60 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 61 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 62 GLOBAL UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)

FIGURE 63 NORTH AMERICA UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)

FIGURE 64 EUROPE UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)

FIGURE 65 Asia-pacific Underactive bladder market: COMPANY SHARE 2021 (%)

View Detailed Information

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

What is the growth rate of the Underactive Bladder Market?

The Underactive Bladder Market will grow at a CAGR of 5.1% by forecast.

Which factors are poised to restrict the market growth?

The high cost of Research and Development (R&D) restricts market growth.

Who are the major players operating in the Underactive Bladder Market?

The major players operating in the Underactive Bladder Market are Astellas Pharma Inc., Aurobindo Pharma., Boehringer Ingelheim International GmbH, Macleods Pharmaceuticals Ltd., Orion Corporation, ONO PHARMACEUTICAL CO., LTD., Novartis AG, Pfizer Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Almirall, S.A, Glenwood, Vesiflo, Inc., and Alkem Labs. among others.

What are the major countries covered in the Market?

The major countries covered in the Underactive Bladder Market are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.

السوق العالمية للمثانة غير النشطة – اتجاهات الصناعة والتوقعات حتى عام 2029

السوق العالمية للمثانة غير النشطة – اتجاهات الصناعة والتوقعات حتى عام 2029

تحليل ورؤى حول سوق المثانة غير النشطة

ديناميكيات سوق المثانة غير النشطة العالمية

تأثير ما بعد كوفيد-19 على سوق المثانة غير النشطة العالمية

تحليل إقليمي/رؤى حول سوق المثانة غير النشطة العالمية

تحليل المشهد التنافسي وحصة سوق المثانة غير النشطة العالمية

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Table of Content

List of Table

List of Figure

منهجية البحث

التخصيص متاح

Frequently Asked Questions

التقارير

رؤى السوق

يدعم

حلول

السوق العالمية للمثانة غير النشطة – اتجاهات الصناعة والتوقعات حتى عام 2029

السوق العالمية للمثانة غير النشطة – اتجاهات الصناعة والتوقعات حتى عام 2029

تحليل ورؤى حول سوق المثانة غير النشطة

ديناميكيات سوق المثانة غير النشطة العالمية

تأثير ما بعد كوفيد-19 على سوق المثانة غير النشطة العالمية

تحليل إقليمي/رؤى حول سوق المثانة غير النشطة العالمية

تحليل المشهد التنافسي وحصة سوق المثانة غير النشطة العالمية

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Table of Content

List of Table

List of Figure

منهجية البحث

التخصيص متاح

Frequently Asked Questions

تصفح الصفحات ذات الصلة